This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Small-Cap Winners & Losers

Small-cap stocks hovered above the broader market Wednesday for most of the day as upbeat news surfaced from a variety of sectors.

Cypress Bioscience (CYPB) was still riding high after surging late Tuesday on positive preliminary results from a late-stage trial of milnacipran for treatment of fibromyalgia syndrome. Shares nearly doubled at $16.37 after a CIBC World Markets analyst upped the stock to outperform. Forest Laboratories (FRX), which jointly announced these results with Cypress, lately added 2.2% to $53.

Semiconductor Advanced Analogic Technologies (AATI) also garnered an upgrade -- to buy from hold, at Needham & Co. -- after Tuesday's after-hours announcement of a favorable "initial determination" ruling from a patent-infringement case brought by Linear Technology (LLTC). After an extended-trading leap, AnalogicTech shares still climbed 16.5% higher to $9.33. Linear slid 3.6% to $35.79.

Cypress and Analogic both supported the Russell 2000, which enjoyed a few hours on the upswing before careening down to flat-line along with the rest of the market. The index was off 0.4% at 836.54.

Also among small-cap gainers today was Mesa Laboratories (MLAB - Get Report). Shares vaulted 22.6% to $22.68 after the Colorado-based medical-equipment maker reported fiscal fourth-quarter earnings of $1.4 million, or 44 cents a share, compared with 27 cents a share a year ago. Sales soared 53.6% to $5.3 million.

SenoRx (SENO), based in California, said the Food and Drug Administration cleared for commercialization its Multi-Lumen Radiation Balloon Applicator for brachytherapy in breast cancer patients. (Brachytherapy involves implanting small radioactive "seeds" that kill cancer cells.) Shares jumped 13.5%, or $1.08, to $9.08.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
FRX $99.00 -0.77%
MLAB $82.50 -9.52%
AAPL $94.02 -2.67%
FB $104.07 -5.81%
GOOG $683.57 -3.45%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs